Empagliflozin reduces Ca/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes by Mustroph, Julian et al.
Empagliﬂozin reduces Ca/calmodulin-dependent
kinase II activity in isolated ventricular cardiomyocytes
Julian Mustroph1, Olivia Wagemann1, Charlotte M. Lücht1, Maximilian Trum1, Karin P. Hammer1, Can Martin
Sag1, Simon Lebek1, Daniel Tarnowski1, Jörg Reinders2, Filippo Perbellini3, Cesare Terracciano3, Christof
Schmid4, Simon Schopka4, Michael Hilker4, York Zausig5, Steffen Pabel1, Samuel T. Sossalla1,6, Frank
Schweda7, Lars S. Maier1 and Stefan Wagner1*
1Department of Internal Medicine II, University Medical Center Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Germany; 2Leibniz Research Centre for Working
Environment and Human Factors, University of Dortmund, Dortmund, Germany; 3Laboratory of Myocardial Electrophysiology, Imperial Centre for Translational and
Experimental Medicine, Imperial College London, London, UK; 4Department of Cardiothoracic Surgery, University Medical Center Regensburg, Franz-Josef-Strauß-Allee 11,
93053, Regensburg, Germany; 5Department of Anesthesiology, University Medical Center Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Germany; 6Clinic for
Cardiology and Pneumology, University Medical Center Göttingen, Göttingen, Germany; 7Department of Physiology, University of Regensburg, Regensburg, Germany
Abstract
Aims The EMPA-REG OUTCOME study showed reduced mortality and hospitalization due to heart failure (HF) in diabetic
patients treated with empagliﬂozin. Overexpression and Ca2+-dependent activation of Ca2+/calmodulin-dependent kinase II
(CaMKII) are hallmarks of HF, leading to contractile dysfunction and arrhythmias. We tested whether empagliﬂozin reduces
CaMKII- activity and improves Ca2+-handling in human and murine ventricular myocytes.
Methods and results Myocytes from wild-type mice, mice with transverse aortic constriction (TAC) as a model of HF, and
human failing ventricular myocytes were exposed to empagliﬂozin (1 μmol/L) or vehicle. CaMKII activity was assessed by
CaMKII–histone deacetylase pulldown assay. Ca2+ spark frequency (CaSpF) as a measure of sarcoplasmic reticulum (SR)
Ca2+ leak was investigated by confocal microscopy. [Na+]i was measured using Na
+/Ca2+-exchanger (NCX) currents (whole-cell
patch clamp). Compared with vehicle, 24 h empagliﬂozin exposure of murine myocytes reduced CaMKII activity (1.6 ± 0.7
vs. 4.2 ± 0.9, P < 0.05, n = 10 mice), and also CaMKII-dependent ryanodine receptor phosphorylation (0.8 ± 0.1 vs. 1.0 ± 0.1,
P < 0.05, n = 11 mice), with similar results upon TAC. In murine myocytes, empagliﬂozin reduced CaSpF (TAC: 1.7 ± 0.3 vs.
2.5 ± 0.4 1/100 μm1 s1, P < 0.05, n = 4 mice) but increased SR Ca2+ load and Ca2+ transient amplitude. Importantly,
empagliﬂozin also signiﬁcantly reduced CaSpF in human failing ventricular myocytes (1 ± 0.2 vs. 3.3 ± 0.9, P < 0.05,
n = 4 patients), while Ca2+ transient amplitude was increased (F/F0: 0.53 ± 0.05 vs. 0.36 ± 0.02, P < 0.05, n = 3 patients).
In contrast, 30 min exposure with empagliﬂozin did not affect CaMKII activity nor Ca2+-handling but signiﬁcantly reduced
[Na+]i.
Conclusions We show for the ﬁrst time that empagliﬂozin reduces CaMKII activity and CaMKII-dependent SR Ca2+ leak.
Reduced Ca2+ leak and improved Ca2+ transients may contribute to the beneﬁcial effects of empagliﬂozin in HF.
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Background
Treatment of diabetic patients with cardiovascular disease
with the novel anti-diabetic drug empagliﬂozin, a selective
inhibitor of sodium-dependent glucose transporter 2 (SGLT2)
in the renal proximal tubules, reduced the incidence of
cardiovascular death by 38% (EMPA-REG OUTCOME trial,
n = 7020 patients).1 The underlying mechanisms are hotly
discussed. Surprisingly, the beneﬁcial effects were not driven
by a reduction in ischaemic endpoints (stroke or myocardial
infarction) but by a reduction in the risk of hospitalization
for heart failure (HF).1 In addition, empagliﬂozin exerts the
same beneﬁcial cardiovascular effects after adjustment
for ischaemic risk factors (blood pressure, low-density
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lipoprotein cholesterol, HbA1c).2 In a mediation analysis of
this trial, changes in haematocrit (and haemoglobin) but
not HbA1c appeared to be the variables with the largest
impact on the risk of cardiovascular death.3 This argues
strongly against glycaemic control as the underlying cardio-
protective mechanism.4 As a consequence, large Phase III
trials are currently initiated that investigate empagliﬂozin
in non-diabetic patients with HF (EMPEROR and EMPERIAL
trial programs). Interestingly, in a non-diabetic mouse
model of afterload-induced HF, empagliﬂozin prevented
worsening of left ventricular function.5 Overexpression
and activation of Ca2+/calmodulin-dependent kinase II
(CaMKII) are hallmarks of HF3 and also found in diabetic
patients,4 leading to increased diastolic Ca2+ leak from the
sarcoplasmic reticulum (SR) and reduced SR Ca2+ load,
causing contractile dysfunction and arrhythmias.3 Interest-
ingly, CaMKII is activated by increased cytosolic Ca2+
concentrations.
Aims
We tested whether empagliﬂozin inhibits CaMKII activity and
diastolic SR Ca2+ leak in cultured human and murine ventric-
ular cardiomyocytes.
Methods
Experiments conform to the Declaration of Helsinki and
were approved by local authorities. Left ventricular myocar-
dium was acquired from explanted hearts of heart trans-
plant recipients with end-stage HF (patient characteristics
in Table S1). Atrial tissue was acquired from patients
undergoing coronary artery bypass grafting. Written con-
sent had been given prior to tissue donation. For some ex-
periments, C57BL/6 mice (8–12 weeks) were used, and HF
was induced by transverse aortic constriction (TAC; 5 weeks,
as previously described6). Echocardiographic data on heart
structure and function of TAC mice are shown in Table
S2. Isolated cardiomyocytes were exposed to either vehicle
or 1 μmol/L empagliﬂozin. This concentration is in the
range of the typical plasma concentration upon 25 mg q.
d. oral treatment of patients.7 CaMKII activity was mea-
sured by CaMKII–histone deacetylase (HDAC4) pulldown
normalized to CaMKII expression.8 Cell isolation, culture,
Western blots, and measurement of Na+ and Ca2+ handling
were employed as previously described.9,10 Cardiomyocyte
survival after 30 min or 24 h exposure to empagliﬂozin
or vehicle control was not signiﬁcantly different. Whole-cell
voltage-clamp patch-clamp experiments were performed
as described previously, and subsarcolemmal [Na+]i
was calculated using the Nernst equation.11 Liquid
chromatography–mass spectrometry (LC–MS) from SGLT2
gel bands from non-failing and failing human myocardium
and high-resolution selected reaction monitoring (HR-SRM)
for SGLT2 from human failing myocardium, and murine
kidney and myocardium were performed as previously
described. Data are shown as mean ± SEM; normality was
tested using the Shapiro–Wilk normality test and paramet-
ric [ANOVA or (paired) Student’s t-test] or non-parametric
(Mann–Whitney test or Wilcoxon signed-rank test) tests
were used as appropriate.
An extended methods section can be found in the
Supporting Information.
Results
CaMKII activity was measured using CaMKII pulldown by
HDAC4 binding. Interestingly, 24 h exposure of murine wild-
type (WT) ventricular cardiomyocytes to empagliﬂozin
(1 μmol/L) signiﬁcantly reduced CaMKII activity from
4.2 ± 0.9 to 1.6 ± 0.7 (P < 0.05, n = 10 mice, Figure 1A). As
CaMKII is a critical regulator of Ca2+ handling, we assessed
SR Ca2+ load (caffeine transients, 10 mmol/L) and diastolic
Ca2+ leak (Ca2+ sparks) in isolated murine WT ventricular
cardiomyocytes. Interestingly, compared with vehicle, 24 h
empagliﬂozin exposure signiﬁcantly increased SR Ca2+ load
(Figure 1B). Without post-translational modiﬁcations of
cardiac ryanodine receptor (RyR2) that directly reduce their
open probability, increased luminal (SR) Ca2+ would lead to
increased Ca2+ leak.12 However, compared with vehicle,
24 h empagliﬂozin exposure did not increase Ca2+ spark
frequency (CaSpF) as a measure of Ca2+ leak but signiﬁcantly
reduced the SR Ca2+ leak/SR Ca2+ load ratio (Figure 1C).
Accordingly, CaMKII-dependent phosphorylation of RyR2 (at
serine 2814) was signiﬁcantly decreased, while the protein
kinase A (PKA)-dependent phosphorylation (at S2809) was
unaltered upon 24 h exposure to empagliﬂozin (Figure 1D).
Interestingly, phosphorylation of phospholamban (PLN) at
threonine 17, perhaps the most frequently studied CaMKII
phospho-site, was signiﬁcantly reduced by 24 h empagliﬂozin
exposure (Figure 1E).
In order to test if empagliﬂozin also affects CaMKII-
dependent SR Ca2+ leak in HF, ventricular myocytes were
isolated from mice with HF upon TAC and from explanted
hearts of patients with end-stage HF. Intriguingly, compared
with vehicle, 24 h empagliﬂozin exposure signiﬁcantly
reduced CaSpF in TAC myocytes and human failing ventric-
ular cardiomyocytes (Figure 2A). This empagliﬂozin effect
was not restricted to HF. Treatment with empagliﬂozin also
reduced CaSpF in human atrial cardiomyocytes (Figure 2A).
Accordingly, 24 h empagliﬂozin exposure signiﬁcantly re-
duced CaMKII activity (CaMKII pulldown by HDAC binding)
and CaMKII-dependent RyR2 and PLN phosphorylation in
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failing TAC cardiomyocytes (Figure 2B) and CaMKII-
dependent RyR2 phosphorylation in human failing
ventricular myocytes (Figure 2C). PKA-dependent RyR2
phosphorylation (at 2809), on the other hand, was not
affected by empagliﬂozin in both in TAC and human failing
cardiomyocytes (Figure 2B and C). Expression of neither
RyR2 nor PLN was signiﬁcantly altered.
Increased SR Ca2+ load can lead to increased systolic SR
Ca2+ release and improved contractile function. We show
here that, compared with vehicle, 24 h empagliﬂozin
exposure signiﬁcantly increased Ca2+ transient amplitude
(CaTransAmpl) in both healthy murine ventricular myocytes
and failing ventricular myocytes from TAC mice and human
failing hearts (Figure 3A). This increase was less pronounced
Figure 1 (A) Original Western blots of CaMKII–HDAC pulldown, total HDAC, CaMKII expression, and GADPH from lysates of murine ventricular
cardiomyocytes exposed to empagliﬂozin (Empa, 1 μmol/L) for 24 h. (B) Mean data for caffeine-induced Ca2+ transient amplitude (CaffTransAmpl)
as a measure of SR Ca2+ load in murine ventricular cardiomyocytes after 24 h empagliﬂozin exposure (Fura-2). (C) Original confocal linescans (left
panel) and mean data for CaSpF (Fluo-4, middle panel) and SR Ca
2+
leak normalized to SR Ca
2+
load (right panel) in murine ventricular myocytes upon
24 h empagliﬂozin exposure. Ca2+ leak was calculated as CaSpF × CaSpAmpl × CaSpWidth (full width at half maximum) × CaSpDuration (full duration at
half maximum) and divided by CaffTransAmpl. (D) Original Western blots and mean data for phospho-S2814/RyR2 ratio, phospho-S2809/RyR2 ratio,
and RyR2 expression from murine ventricular cardiomyocytes after 24 h empagliﬂozin (E) or vehicle (V) exposure. (E) Original Western blots and mean
data for phospho-T17/PLN ratio, as well as PLN and SERCA expression from murine ventricular cardiomyocytes after 24 h empagliﬂozin (E) or vehicle
(V) exposure. (A–C) *P < 0.05 Mann–Whitney test. (D and E) *P < 0.05 Wilcoxon signed-rank test or paired t-test as appropriate. CaMKII, Ca2+/cal-
modulin-dependent kinase II; CaSpF, Ca2+ spark frequency; HDAC, histone deacetylase; PLN, phospholamban; SR, sarcoplasmic reticulum.
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Figure 2 (A) Mean data for CaSpF in failing murine ventricular myocytes (TAC, left panel), human atrial myocytes (middle panel), or human failing
ventricular cardiomyocytes (right panel, original line scans also shown). *P < 0.05 Mann–Whitney test. (B) Left panel: original Western blots of
CaMKII–HDAC pulldown, total HDAC, CaMKII expression, and GADPH, as well as mean data of CaMKII activity normalized to CaMKII expression from
lysates of murine TAC ventricular cardiomyocytes exposed to empagliﬂozin (Empa, 1 μmol/L) for 24 h. Middle panel: original Western blots and mean
data for phospho-S2814/RyR2 ratio and phospho-S2809/RyR2 ratio from murine TAC ventricular cardiomyocytes after 24 h empagliﬂozin (E) or vehicle
(V) exposure. Right panel: original Western blots and mean data for phospho-T17/PLN ratio, as well as PLN and SERCA expression from murine ven-
tricular cardiomyocytes after 24 h empagliﬂozin (E) or vehicle (V) exposure. (C) Original Western blots and mean data for phospho-S2814/RyR2 ratio,
phospho-S2809/RyR2 ratio, and RyR2 expression from human failing ventricular cardiomyocytes. (B and C) *P < 0.05 Wilcoxon signed-rank test or
paired t-test as appropriate. CaMKII, Ca
2+
/calmodulin-dependent kinase II; CaSpF, Ca
2+
spark frequency; HDAC, histone deacetylase; PLN, phospholam-
ban; TAC, transverse aortic constriction.
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Figure 3 (A) Mean data for Ca2+ transient amplitude (CaTransAmpl) in healthy murine ventricular myocytes (left panel), failing murine ventricular
myocytes (TAC, middle panel, both Fura-2), or human failing ventricular cardiomyocytes (right panel, Fluo-4) elicited by electrical ﬁeld stimulation
at indicated frequencies. (B) Mean data of subsarcolemmal [Na+]i in murine WT CM (left panel, calculated from Na
+/Ca2+-exchanger (NCX) current
measured by whole-cell patch clamp), diastolic [Ca
2+
]i (Fura-2, middle panel) in murine WT CM (electrical ﬁeld stimulation at indicated frequencies),
and CaMKII activity (CaMKII–HDAC pulldown) in human failing ventricular tissue after 30 min incubation with empagliﬂozin. (C) Mean data of [Na+]i
[SBFI (sodium-binding benzofuran isophthalate = sodium indicator) ﬂuorescence, left panel] and diastolic [Ca
2+
]i (Fura-2, right panel) in murine WT
CM after 24 h empagliﬂozin exposure. (D) Representative chromatographic images of HR-SRM analyses of human and murine SGLT2 protein. Two
proteotypic SGLT2 peptides that are identical between mouse and human were used for highly sensitive detection of SGLT2 (top panel,
VCGTEVGCSNIAYPR; bottom panel, GTVGGYFLAGR). For each peptide, six transitions (y4, 8, 9, 10, 11, 13 or y4, 5, 6, 7, 8, 9, respectively) were detected.
In contrast to clear SGLT2 expression in mouse kidney (at retention times of 65 or 72.5 min), no signal was detected neither in WT or TAC mouse hearts
nor in human failing myocardium. Of note, the signal at 71.5 min retention time in human HF is unspeciﬁc. *P < 0.05 (Mann–Whitney test), #P < 0.05
two-way ANOVA. CaMKII, Ca2+/calmodulin-dependent kinase II; HDAC, histone deacetylase; HR-SRM, high-resolution selected reaction monitoring;
TAC, transverse aortic constriction.
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in WT compared with β-adrenergic stimulation (isoproterenol
(ISO) 107 M). At 1 Hz, ISO increased CaTransAmpl 2.1 ± 0.65-
fold relative to vehicle (n = 9) but empagliﬂozin increased
1.6 ± 0.35-fold only (n = 9 vs. 13 mice).
In contrast to 24 h exposure, acute empagliﬂozin exposure
for 30 min did not reduce CaSpF (in healthy murine ventricu-
lar myocytes, TAC myocytes, or human failing ventricular
myocytes) or SR Ca2+ load (murine ventricular myocytes; data
not shown). Furthermore, acute empagliﬂozin exposure for
30 min also did not alter diastolic Ca2+ concentration (WT
myocytes) or CaMKII activity (human failing ventricular
tissue; Figure 3B, n = 11 patients). This suggests that direct
inhibitory effects of empagliﬂozin on CaMKII or RyR2 are
unlikely. Interestingly, consistent with previous data,5,6 acute
(30 min) empagliﬂozin exposure signiﬁcantly reduced
subsarcolemmal [Na+]i (measured by Na
+/Ca2+-exchanger
(NCX) currents; Figure 3B). Therefore, empagliﬂozin may
rather directly impair Na+ entry or elimination. To test if
empagliﬂozin may inhibit SGLT2 in the heart, which is a Na+
transporter, we analysed SGLT2 expression in ventricular myo-
cardium from three patients with end-stage HF and three non-
failing donor hearts by LC–MS. No SGLT2 expression was de-
tected using this methodology (data not shown). We further
analysed SGLT2 expression by HR-SRM in murine WT myocar-
dium and kidney, TAC myocardium, and human failing myocar-
dium. In contrast to a robust SGLT2 expression in murine
kidney, no SGLT2 signal was detected in myocardium (Figure
3D), full data set linked in the Supporting Information), which
is in accordance with previous data.13 Thus, cardiac SGLT2
inhibition can be excluded as potential mechanism of action
of empagliﬂozin on the heart. Baartscheer et al. recently pro-
posed that empagliﬂozin may reduce cardiomyocyte [Na+]i
and [Ca2+]i by inhibition of Na
+/H+ exchange.14 As CaMKII is
activated by increased diastolic [Ca2+], which may be a conse-
quence of Na+ entry, we also measured Na+ and diastolic Ca2+.
Interestingly, 24 h empagliﬂozin exposure signiﬁcantly reduced
cytosolic [Na+]i and diastolic [Ca
2+]i (Figure 3C).
Conclusions
We show for the ﬁrst time that empagliﬂozin potently reduces
CaMKII activity in isolated failing and non-failing murine
ventricular myocytes. More importantly, empagliﬂozin also
reduced CaMKII-dependent phosphorylation of RyR2 in not
only murine but also failing human ventricular myocytes. This
results in a signiﬁcantly reduced SR Ca2+ leak and improved
contractility as measured by signiﬁcantly increased Ca2+ tran-
sient amplitude in murine (TAC) and human failing ventricular
myocytes. The mechanism by which empagliﬂozin reduces
CaMKII activity has yet to be discerned, but our data demon-
strate that empagliﬂozin may be useful in the treatment of
pathologies with increased CaMKII activity, such as HF.
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Table S1. Clinical characteristics of patient, from which atrial
biopsies were obtained (upper table), or from which left ven-
tricular tissue of explanted hearts (after heart transplantation,
lower table) was used. y = yes, n = no, Nr = number,
CAD = coronary artery disease, ICM = ischemic cardiomyopa-
thy, DCM = dilated cardiomyopathy, EF = ejection fraction in
%, LVEDD = left ventricular enddiastolic diameter in mm,
m = male, SR = sinus rhythm, CABG = coronary artery bypass
graft, valves = valvular dysfunction, MR = mitral regurgitation,
TR = tricuspid regurgitation x° = indicated severity degree ac-
cording to international standards, Art Hyp = arterial hyper-
tension, KD = kidney disease, GFR = glomerular ﬁltration rate
in ml/min, NTproBNP in pg/ml (internal cutoff <150 pg/ml).
Table S2. Echocardiographic data obtained from 16 mice.
OP = TAC surgery, bpm = beats per minute, LV = left ventricle,
AWThd = anterior wall thickness in diastole, PWThd = posterior
wall thickness in diastole, LVIDs = left ventricular internal di-
ameter in systole, LVIDd = left ventricular internal diameter
in diastole, *P < 0.05 versus respective pre-OP-measurement
(Student’s t-test).
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